Roger Adsett

“The Company's seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the "2027 Annual Meeting") or until a successor has been duly elected or appointed, by the following votes:”

“On January 28, 2026, the Board of Directors (the “Board”) of Definium Therapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, increased the size of the Board from six (6) to seven (7) directors and appointed Roger Adsett to fill the vacancy on the Board, effective January 29, 2026, with a term expiring at the Company's annual general meeting of shareholders to be held in 2026, or until his successor is duly elected or appointed, or until his earlier death, resignation or removal.”